TGFB1 and neoplasm: Pancreatic cancer models demonstrate that TGF-β/PD-L1 blockade enhances effector DCs activity [287], whereas TGF-β receptor knockdown in DCs boosts IFN-γ production and tumor cell clearance in cholangiocarcinoma models [288].